Dexmedetomidine for the treatment of hyperactive delirium refractory to haloperidol in non-intubated patients
- PMID: 27501127
- PMCID: PMC4958851
- DOI: 10.21037/jtd.2016.05.47
Dexmedetomidine for the treatment of hyperactive delirium refractory to haloperidol in non-intubated patients
Conflict of interest statement
Comment in
-
Dexmedetomidine, agitated delirium, and "off-label" drugs.J Thorac Dis. 2016 Oct;8(10):E1432-E1434. doi: 10.21037/jtd.2016.10.02. J Thorac Dis. 2016. PMID: 27867651 Free PMC article. No abstract available.
Comment on
-
Dexmedetomidine for the Treatment of Hyperactive Delirium Refractory to Haloperidol in Nonintubated ICU Patients: A Nonrandomized Controlled Trial.Crit Care Med. 2016 Jul;44(7):1295-306. doi: 10.1097/CCM.0000000000001622. Crit Care Med. 2016. PMID: 26925523 Clinical Trial.
References
-
- Ely EW, Girard TD, Shintani AK, et al. Apolipoprotein E4 polymorphism as a genetic predisposition to delirium in critically ill patients. Crit Care Med 2007;35:112-7. 10.1097/01.CCM.0000251925.18961.CA - DOI - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources